Image-guided percutaneous intralesional administration of mesenchymal stromal cells in subjects with chronic complete spinal cord injury: a pilot study

dc.creatorLarocca, Ticiana Ferreira
dc.creatorMacêdo, Carolina Thé
dc.creatorSouza, Bruno Solano de Freitas
dc.creatorSouza, Yuri M Andrade
dc.creatorVillarreal, Cristiane Flora
dc.creatorMatos, André Costa
dc.creatorSilva, Daniela Nascimento
dc.creatorSilva, Kátia Nunes da
dc.creatorSouza, Clarissa Lima E Moura de
dc.creatorPaixão, Daniela da Silva
dc.creatorBezerra, Milena da Rocha
dc.creatorAlves, Rodrigo Leal
dc.creatorSoares, Milena Botelho Pereira
dc.creatorSantos, Ricardo Ribeiro dos
dc.date2017-08-16T13:45:57Z
dc.date2017-08-16T13:45:57Z
dc.date2017
dc.date.accessioned2023-09-26T23:23:48Z
dc.date.available2023-09-26T23:23:48Z
dc.identifierLAROCCA, T. F. et al. Image-guided percutaneous intralesional administration of mesenchymal stromal cells in subjects with chronic complete spinal cord injury: a pilot study. Cytotherapy, jul. 2017.
dc.identifier1465-3249
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/20638
dc.identifier10.1016/j.jcyt.2017.06.006
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8890122
dc.descriptionBrazilian Development Bank (BNDES).
dc.descriptionThe potential of cell therapies to improve neurological function in subjects with spinal cord injury (SCI) is currently under investigation. In this context, the choice of cell type, dose, route and administration regimen are key factors. Mesenchymal stromal cells (MSCs) can be easily obtained, expanded and are suitable for autologous transplantation. Here we conducted a pilot study that evaluated safety, feasibility and potential efficacy of intralesional MSCs transplantation performed through image-guided percutaneous injection, in subjects with chronic complete SCI. Methods. Five subjects with chronic traumatic SCI (>6 months), at thoracic level, classified as American Spinal Cord Injury Association impairment scale (AIS) grade A, complete injury, were included. Somatosensory evoked potentials (SSEP), spinal magnetic resonance imaging (MRI) and urodynamics were assessed before and after treatment. Autologous MSCs were injected directly into the lesion site through percutaneous injection guided by computerized tomography (CT). Results. Tomography-guided percutaneous cell transplantation was a safe procedure without adverse effects. All subjects displayed improvements in spinal cord independence measure (SCIM) scores and functional independence measure (FIM), mainly due to improvements in bowel movements and regularity. Three subjects showed improved sensitivity to tactile stimulation.Two subjects improved AIS grade to B, incomplete injury, although this was sustained in only one of them during the study follow-up. Conclusion. Autologous bone marrow MSC transplantation, performed through CT-guided percutaneous injection, was shown to be safe and feasible. Further studies are required to demonstrate efficacy of this therapeutic scheme.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsopen access
dc.subjectTerapia celular
dc.subjectEstudo clínico
dc.subjectcélulas estomatais mesenquimais,
dc.subjectLesão da medula espinhal
dc.subjectCell therapy
dc.subjectClinical study
dc.subjectMesenchymal stromal cells
dc.subjectSpinal cord injury
dc.titleImage-guided percutaneous intralesional administration of mesenchymal stromal cells in subjects with chronic complete spinal cord injury: a pilot study
dc.typeArticle


Este ítem pertenece a la siguiente institución